Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Lung cancer biomarker testing : perspective from Europe
Authors:Thunnissen, Erik (Author)
Weynand, Birgit (Author)
Udovicic-Gagula, Dalma (Author)
Brčić, Luka (Author)
Szolkowska, Malgorzata (Author)
Hofman, Paul (Author)
Smojver-Ježek, Silvana (Author)
Anttila, Sisko (Author)
Calabrese, Fiorella (Author)
Kern, Izidor (Author)
Tipology:1.02 - Review Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Keywords:lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing
Year of publishing:2020
Publisher:AME Publishing
COBISS_ID:28071683 Link is opened in a new window
ISSN on article:2226-4477
OceCobissID:17120003 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Soavtor iz Slovenije: Izidor Kern; Opis vira z dne 11. 9. 2020;
Files:.pdf PDF - Presentation file, download (1,80 MB)
URL URL - Source URL, visit
Journal:Transl. lung cancer res.
Pioneer Bioscience
Rights:© Translational Lung Cancer Research
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY-NC-ND 4.0, Creative Commons Attribution Non-Commercial No Derivatives 4.0 International
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:27.05.2020